Vertex Pharmaceuticals Is About to Extend Its Leadership in This Billion-Dollar MarketThe Motley Fool • 02/20/24
Could This News Upset Vertex Pharmaceuticals' Prospects in the Billion-Dollar Pain Management Market?The Motley Fool • 02/18/24
Vertex Pharmaceuticals Will Use $100 Million to Tank Its Own Market Share. Here's Why That's a Smart Move.The Motley Fool • 02/17/24
Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?The Motley Fool • 02/15/24
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood DisordersZacks Investment Research • 02/14/24
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 02/13/24
Vertex Pharmaceuticals Stock Is Approaching a Huge Catalyst, But Is It a Buy?The Motley Fool • 02/08/24
Vertex Pharmaceuticals Has a $10 Billion Opportunity on the Table. Here's How You Can InvestThe Motley Fool • 02/06/24